• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Disease-burden-adapted immunotherapy protocol for primary refractory or high-risk relapsed pediatric acute lymphoblastic leukemia.

作者信息

Khan Sanaa, Vp Krishnan, Krishnan Yamini, Sainulabdin Gazel, Pal Somdipa, Mathews Rincy, Kataria Darshan, Sehgal Kunal, Kanvinde Purva, Harshaprasad Lashkari, Bodhanwala Minnie, Agarwal Bharat, Pandrowala Ambreen, Hiwarkar Prashant

机构信息

Department of Blood and Marrow Transplant Bai Jerbai Wadia Hospital for Children Mumbai India.

Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation MVR Cancer Centre Kozhikode India.

出版信息

Hemasphere. 2024 Jul 29;8(8):e111. doi: 10.1002/hem3.111. eCollection 2024 Aug.

DOI:10.1002/hem3.111
PMID:39081802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11284769/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dd/11284769/36037b95f032/HEM3-8-e111-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dd/11284769/36037b95f032/HEM3-8-e111-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dd/11284769/36037b95f032/HEM3-8-e111-g001.jpg

相似文献

1
Disease-burden-adapted immunotherapy protocol for primary refractory or high-risk relapsed pediatric acute lymphoblastic leukemia.针对原发性难治性或高危复发性儿童急性淋巴细胞白血病的疾病负担适应性免疫治疗方案。
Hemasphere. 2024 Jul 29;8(8):e111. doi: 10.1002/hem3.111. eCollection 2024 Aug.
2
A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.复发或难治性急性淋巴细胞白血病的CD19靶向免疫疗法综述
J Oncol Pharm Pract. 2018 Sep;24(6):453-467. doi: 10.1177/1078155217713363. Epub 2017 Jun 5.
3
Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.小儿复发性或难治性急性淋巴细胞白血病I期和II期试验中的研究性治疗方案。
Expert Opin Investig Drugs. 2021 Jun;30(6):611-620. doi: 10.1080/13543784.2021.1916466. Epub 2021 May 4.
4
Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study.复发/难治性白血病患儿使用贝林妥欧单抗和嵌合抗原受体T细胞疗法：一项病例系列研究。
Front Pediatr. 2023 Jan 16;10:1100404. doi: 10.3389/fped.2022.1100404. eCollection 2022.
5
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia.超越CD19：儿童复发难治性急性白血病靶向免疫治疗的未来发展机遇
Front Pediatr. 2015 Oct 1;3:80. doi: 10.3389/fped.2015.00080. eCollection 2015.
6
Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?复发或难治性 B 细胞急性淋巴细胞白血病的免疫治疗选择：如何选择新批准的药物？
Leuk Lymphoma. 2020 Jan;61(1):7-17. doi: 10.1080/10428194.2019.1641802. Epub 2019 Jul 18.
7
Direct CNS administration of rituximab and epratuzumab in a pediatric patient with relapsed refractory CNS B-cell acute lymphoblastic leukemia.利妥昔单抗和依帕珠单抗直接经中枢神经系统给药用于一名复发难治性中枢神经系统B细胞急性淋巴细胞白血病患儿
Pediatr Blood Cancer. 2022 Jun;69(6):e29664. doi: 10.1002/pbc.29664. Epub 2022 Mar 16.
8
Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.复发/难治性 T 急性淋巴细胞白血病 - 现有治疗选择及未来方向。
Indian J Pediatr. 2024 Feb;91(2):168-175. doi: 10.1007/s12098-023-04745-z. Epub 2023 Aug 29.
9
A review of blinatumomab, a novel immunotherapy.新型免疫疗法——博纳吐单抗综述
J Oncol Pharm Pract. 2016 Aug;22(4):639-45. doi: 10.1177/1078155215618770. Epub 2015 Nov 24.
10
Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.在一名患有4级细胞因子释放综合征的复发/难治性急性淋巴细胞白血病患者中成功重新使用博纳吐单抗。
J Oncol Pharm Pract. 2018 Jan;24(1):67-73. doi: 10.1177/1078155216676633. Epub 2016 Oct 31.

本文引用的文献

1
Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL.blinatumomab 用于治疗儿童和青少年 B 细胞急性淋巴细胞白血病的一线治疗。
J Clin Oncol. 2024 Mar 10;42(8):907-914. doi: 10.1200/JCO.23.01392. Epub 2023 Nov 15.
2
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse.儿童肿瘤协作组 AALL1331：在首次复发的低危 B 细胞 ALL 儿童、青少年和年轻成人中应用blinatumomab 的 III 期临床试验。
J Clin Oncol. 2023 Sep 1;41(25):4118-4129. doi: 10.1200/JCO.22.02200. Epub 2023 May 31.
3
Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
低白血病负荷可提高复发/难治性B细胞急性淋巴细胞白血病患者对blinatumomab的疗效。
Cancer. 2023 May 1;129(9):1384-1393. doi: 10.1002/cncr.34667. Epub 2023 Feb 24.
4
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.伊妥珠单抗奥佐米星作为单药治疗复发/难治性儿童急性淋巴细胞白血病：一项 II 期试验结果。
Leukemia. 2022 Jun;36(6):1516-1524. doi: 10.1038/s41375-022-01576-3. Epub 2022 Apr 25.
5
Should CD19 CAR-T Cells for ALL be Followed by Allogeneic Stem Cell Transplant?急性淋巴细胞白血病的CD19嵌合抗原受体T细胞疗法后是否应进行异基因干细胞移植？
Transplant Cell Ther. 2022 Jan;28(1):1-2. doi: 10.1016/j.jtct.2021.12.002.
6
Minimal Residual Disease Prior to and After Haematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant?儿童和青少年急性淋巴细胞白血病造血干细胞移植前后的微小残留病：何种阴性水平具有相关性？
Front Pediatr. 2021 Nov 5;9:777108. doi: 10.3389/fped.2021.777108. eCollection 2021.
7
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.嵌合抗原受体 T 细胞双重靶向 CD19 和 CD22 治疗儿童和青年复发/难治性 B 细胞急性淋巴细胞白血病患者：一项 1 期试验。
Nat Med. 2021 Oct;27(10):1797-1805. doi: 10.1038/s41591-021-01497-1. Epub 2021 Oct 12.
8
Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.高危 B 细胞前体和 T 细胞复发急性淋巴细胞白血病患儿的风险因素和结局：ALLR3 和 ALL-REZ BFM 2002 临床试验的联合分析。
Eur J Cancer. 2021 Jul;151:175-189. doi: 10.1016/j.ejca.2021.03.034. Epub 2021 May 16.
9
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.Blinatumomab 与化疗治疗高危初发 B 细胞急性淋巴细胞白血病患儿无事件生存的效果：一项随机临床试验。
JAMA. 2021 Mar 2;325(9):843-854. doi: 10.1001/jama.2021.0987.
10
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.Blinatumomab 巩固化疗后与化疗对初发 B 细胞急性淋巴细胞白血病儿童、青少年和年轻成人患者无病生存的影响：一项随机临床试验。
JAMA. 2021 Mar 2;325(9):833-842. doi: 10.1001/jama.2021.0669.